David R. Shprecher, DO, MSCI

Languages

  • English
  • Japanese
  • Spanish

Academic Information

  • Departments: Neurology - Adjunct Associate Professor
  • Divisions: Sleep and Movement Disorders

Board Certification

  • American Board of Psychiatry & Neurology (Neurology)

Academic Office Information

  • 632-832-6500
  • 10515 W. Santa Fe Drive
    Sun City, AZ 85351

Academic Bio

David Shprecher, DO Msci has dedicated his career to improving treatment options for individuals with movement disorders including ataxia, dystonia, essential tremor, Huntington disease, multiple system atrophy, progressive supranuclear palsy, tardive dyskinesia, tics and Tourette syndrome, Lewy body dementia and Parkinson disease. This includes use of botulinum toxin injections and deep brain stimulation to treat movement disorders.

He has maintained an adjunct position with the University of Utah for clinical trials. His primary practice is now located at the Cleo Roberts Clinic in Sun City, Arizona.

Education History

Type School Degree
Graduate Training University of Rochester
Clinical Investigation
M.S.
Fellowship University of Rochester
Movement Disorders
Fellow
Residency University of Utah School of Medicine
Neurology
Resident
Internship University of Utah School of Medicine
Internal Medicine
Intern
Professional Medical Lake Erie College of Osteopathic Medicine
Osteopathic Medicine
D.O.
Undergraduate Cornell University College of Arts and Sciences
Biology
B.S.

Selected Publications

Journal Article

  1. Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan I (2017). Genetic influences on cognition in progressive supranuclear palsy. Mov Disord, 32(12), 1764-1771.
  2. Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J, ENGENE PSP study (2017). Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord, 35, 75-81.
  3. Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler D (11/8/2016). Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (N Y), 6.
  4. Kious BM, Jimenez-Shahed J, Shprecher DR (2016). Treatment-refractory Tourette Syndrome. Prog Neuropsychopharmacol Biol Psychiatry, 70, 227-36.
  5. Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, ONeill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E (2016). Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA, 316(1), 40-50.
  6. Litvan I, Lees PS, Cunningham CR, Rai SN, Cambon AC, Standaert DG, Marras C, Juncos J, Riley D, Reich S, Hall D, Kluger B, Bordelon Y, Shprecher DR, for ENGENE-PSP (2016). Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. Mov Disord, 31(5), 644-52.
  7. Brody DM, Litvan I, Warner S, Riley DE, Hall DA, Kluger BM, Shprecher DR, Cunningham CR (2016). Relationship between uric acid levels and progressive supranuclear palsy. Mov Disord, 31(5), 663-7.
  8. Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP (2015). The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. Mol Neurodegener, 10, 50.
  9. Shprecher D, Rubenstein L, Gannon K, Frank S, Kurlan R (2014). Temporal Course of the Tourette Syndrome Clinical Triad. Tremor Other Hyperkinet Mov (N Y).
  10. Shprecher D, Schrock L, Himle M (2014). Neurobehavioral aspects, pathophysiology, and management of Tourette's syndrome. Curr Opin Neurol, 27(4), 484-92.
  11. Shprecher D, Gannon K, Agarwal N, Shi X, Anderson J (2014). Elucidating the mechanism of tic improvement in Tourette syndrome: a pilot study. Tremor Other Hyperkinet Mov (N Y).
  12. Duff K, Shprecher D, Litvan I, Gerstenecker A, Mast B on behalf of the ENGENE investigators (2013). Correcting for demographic variables on the modified Telephone Interview for Cognitive Status. Am J Geriatr Psychiatry.
  13. Shprecher D, Noyes Katia, Biglan Kevin, Wang Dongwen, Dorsey Ray E, Kurlan Roger, Adams Michael Jacob (2012). Willingness of Parkinson Disease Patients to Participate in Research Using Internet Based Technology. Telemed J E Health.
  14. Dorsey ER, Voss TS, Shprecher DR, Deuel LM, Beck CA, Gardiner IF, Coles MA, Burns RS, Marshall FJ, Biglan KM (2010). A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups. Mov Disord, 25(13), 2128-35.
  15. Shprecher D, Mehta L (2010). The syndrome of delayed post-hypoxic leukoencephalopathy. NeuroRehabilitation, 26(1), 65-72.
  16. Shprecher D, Kurlan R (2009). The management of tics. Mov Disord, 24(1), 15-24.
  17. Shprecher D, Schwalb J, Kurlan R (2008). Normal pressure hydrocephalus: diagnosis and treatment. Curr Neurol Neurosci Rep, 8(5), 371-6.
  18. Shprecher DR, Flanigan KM, Smith AG, Smith SM, Schenkenberg T, Steffens J (2008). Clinical and diagnostic features of delayed hypoxic leukoencephalopathy. J Neuropsychiatry Clin Neurosci, 20(4), 473-7.

Review

  1. Lyon G, Shprecher D, Coffey B, Kurlan R (July 2010). Tourette’s Disorder. [Review]. Curr Treat Options Neurol, 12(4), 274-286.

Case Report

  1. Shprecher D, Grossmann K, Tward J (2014). Sustained remission of Parkinson disease associated melanoma with immunotherapy. Parkinsonism Relat Disord.

Editorial

  1. Shprecher DR, Majersik JJ (2017). The virtual house call: A 21st-century innovation in the care of patients with Parkinson disease. 89(11), 1103-1104.

Clinical Trials